{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:36:16Z","timestamp":1786988176818,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejso.2025.111155","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:56:21Z","timestamp":1761785781000},"page":"111155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-EGFR plus chemotherapy vs. chemotherapy alone in RAS wild-type colorectal liver metastases: A meta-analysis of survival outcomes in resectable and unresectable settings"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9712-2553","authenticated-orcid":false,"given":"Ottavia","family":"Cicerone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-0233","authenticated-orcid":false,"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-8441","authenticated-orcid":false,"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vanoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-9151","authenticated-orcid":false,"given":"Marcello","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2025.111155_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"10.1016\/j.ejso.2025.111155_bib2","article-title":"Challenges and opportunities for precision surgery for colorectal liver metastases","volume":"16","author":"O'Connell","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ejso.2025.111155_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101849","article-title":"Surgical resection in colorectal liver metastasis: an umbrella review","volume":"16","author":"Milazzo","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ejso.2025.111155_bib4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4240\/wjgs.v13.i8.756","article-title":"Borderline resectable for colorectal liver metastases: present status and future perspective","volume":"13","author":"Kitano","year":"2021","journal-title":"World J Gastrointest Surg"},{"issue":"8","key":"10.1016\/j.ejso.2025.111155_bib5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2025.111155_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejso.2025.111155_bib7","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9617","key":"10.1016\/j.ejso.2025.111155_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejso.2025.111155_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.111155_bib10","series-title":"Cochrane handbook for systematic reviews of interventions version 64: cohchrane","article-title":"Chapter 10: analysing data and undertaking meta-analyses","author":"Deeks","year":"2023"},{"issue":"10","key":"10.1016\/j.ejso.2025.111155_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111155_bib12","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1634\/theoncologist.2020-0563","article-title":"Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS\/BRAF wild-type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase II trial","volume":"26","author":"Hu","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejso.2025.111155_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00423-022-02434-7","article-title":"A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study","volume":"407","author":"Matsumura","year":"2022","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ejso.2025.111155_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejca.2022.07.012","article-title":"FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0\/1 resection of RAS wild-type colorectal cancer liver metastases - the PARLIM trial (AIO KRK 0314)","volume":"173","author":"Modest","year":"2022","journal-title":"Eur J Cancer"},{"issue":"35","key":"10.1016\/j.ejso.2025.111155_bib15","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111155_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.111155_bib17","article-title":"Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer\u2014is it justified?","volume":"9","author":"Peixoto","year":"2025","journal-title":"ESMO Gastrointestinal Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111155_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111155_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12876-017-0694-6","article-title":"Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"10.1016\/j.ejso.2025.111155_bib20","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41416-024-02604-y","volume":"130","author":"Karapetis","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.111155_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ijc.33775","article-title":"Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306)","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"55","key":"10.1016\/j.ejso.2025.111155_bib22","doi-asserted-by":"crossref","first-page":"93856","DOI":"10.18632\/oncotarget.21291","article-title":"Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the new EPOC trial","volume":"8","author":"Pugh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2025.111155_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpb.2016.01.132","article-title":"EGFR ligand expression levels and detriment from cetuximab in patients with operable liver metastases from colorectal cancer","volume":"18","author":"Pugh","year":"2016","journal-title":"HPB"},{"issue":"5","key":"10.1016\/j.ejso.2025.111155_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamaoncol.2015.6065","article-title":"Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer","volume":"2","author":"Seligmann","year":"2016","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejso.2025.111155_bib25","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2023.41.16_suppl.3577","article-title":"Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial","volume":"41","author":"Pugh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejso.2025.111155_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e15079","article-title":"Searching for predictive biomarkers on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases: an expended biomarker analysis based on BELIEF study","volume":"34","author":"Xu","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111155_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw370.89","article-title":"Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): a retrospective biomarker analysis from a Chinese trial","volume":"27","author":"Xu","year":"2016","journal-title":"Ann Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325015835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325015835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:57:50Z","timestamp":1767945470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325015835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0748798325015835"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111155","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EGFR plus chemotherapy vs. chemotherapy alone in RAS wild-type colorectal liver metastases: A meta-analysis of survival outcomes in resectable and unresectable settings","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111155"}}